Dual MAb therapy targets CSCs, prevents resistance
Combining two monoclonal antibody (MAb) cancer therapies as one treatment not only shrank bulk tumors, but also targeted the cancer stem cells (CSCs) that can be responsible for disease relapse, according to a new Chinese study reported in the March 8, 2017, edition of Science Translational Medicine.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST